Is Atripla a feasible switch option in patients with an existing M184V mutation?

被引：0
|
作者：
Rockwood, N. [1 ]
Singh, G. Jagjit [1 ]
Nelson, M. [1 ]
机构：
[1] Chelsea & Westminster Hosp, London, England
来源：
HIV MEDICINE | 2011年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：29 / 29
页数：1
相关论文
共 50 条
  • [21] Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Adults With HIV and M184V/I Mutation
    Perez-Valero, Ignacio
    Llibre, Josep M.
    Castagna, Antonella
    Pulido, Federico
    Molina, Jean-Michel
    Esser, Stefan
    Margot, Nicolas
    Shao, Yongwu
    Temme, Lauren
    Piontkowsky, David
    McNicholl, Ian R.
    Haubrich, Richard
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2021, 86 (04) : 490 - 495
  • [22] Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients
    Olearo, Flaminia
    Huyen Nguyen
    Bonnet, Fabrice
    Yerly, Sabine
    Wandeler, Gilles
    Stoeckle, Marcel
    Cavassini, Matthias
    Scherrer, Alexandra
    Costagiola, Dominique
    Schmid, Patrick
    Gunthard, Huldrych F.
    Bernasconi, Enos
    Boeni, Jurg
    Monforte, Antonella D'Arminio
    Zazzi, Maurizio
    Rossetti, Barbara
    Neau, Didier
    Bellecave, Pantxika
    Rijnders, Bart
    Reiss, Peter
    Wit, Ferdinand
    Kouyos, Roger
    Calmy, Alexandra
    OPEN FORUM INFECTIOUS DISEASES, 2019, 6 (10):
  • [23] The impact of the M184V resistance mutation on treatment outcomes in patients with HIV infection: a systematic review and meta-analysis
    Kandeel, Mahmoud
    AIDS REVIEWS, 2023, 25 (03) : 136 - 144
  • [24] Sustained viral suppression after switch to bictegravir/emtricitabine/tenofovir alafenamide among clinical trial participants with pre-existing M184V/I
    Andreatta, K.
    Acosta, R.
    D'Antoni, M. L.
    Porter, D. P.
    Chang, S.
    Martin, R.
    Willkom, M.
    McNicholl, I.
    Gallant, J.
    Graham, H.
    Collins, S.
    Martin, H.
    Kabagambe, S.
    White, K.
    HIV MEDICINE, 2021, 22 : 31 - 31
  • [25] The impact of M184V/I mutation on the efficacy of abacavir/lamivudine/dolutegravir regimens prescribed in treatment-experienced patients
    Olearo, F.
    Nguyen, H.
    Bonnet, F.
    Wandeler, G.
    Stoeckle, M.
    Battig, V.
    Cavassini, M.
    Scherrer, A.
    Schmid, P.
    Bucher, H.
    Gunthard, H.
    Boni, J.
    Yerly, S.
    Monforte, A. D'Armino
    Zazzi, M.
    Bellerive, P.
    Rijnders, B.
    Reiss, P.
    Wit, F.
    Kouyos, R.
    Calmy, A.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21
  • [26] The effect of lamivudine therapy and M184V on the antiretroviral activity of didanosine
    Eron, Joseph J., Jr.
    Bosch, Ronald J.
    Bettendorf, Daniel
    Petch, Leslie
    Fiscus, Susan
    Frank, Ian
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2007, 45 (02) : 249 - 251
  • [27] The M184V mutation in reverse transcriptase can delay reversion of attenuated variants of simian immunodeficiency virus
    Whitney, JB
    Oliveira, M
    Detorio, M
    Guan, YJ
    Wainberg, MA
    JOURNAL OF VIROLOGY, 2002, 76 (17) : 8958 - 8962
  • [28] Multiple effects of the M184V resistance mutation in the reverse transcriptase of human immunodeficiency virus type 1
    Turner, D
    Brenner, B
    Wainberg, MA
    CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2003, 10 (06) : 979 - 981
  • [29] Salvage therapy with abacavir in HIV-1-infected patients with previously documented M184V mutation: a possibility of NRTI recycling
    Maggiolo, F
    Callegaro, A
    Arici, C
    Quinzan, G
    Gregis, G
    Ripamonti, D
    Tebaldi, A
    Goglio, A
    Suter, F
    ANTIVIRAL THERAPY, 2003, 8 (02) : 121 - 126
  • [30] Rationale for maintenance of the M184V resistance mutation in human immunodeficiency virus type 1 reverse transcriptase in treatment experienced patients
    Turner, D
    Brenner, BG
    Routy, JP
    Petrella, M
    Wainberg, MA
    MICROBIOLOGICA, 2004, 27 (02): : 31 - 39
12345